• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

    2/9/24 9:59:03 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5 )*

                

    Prestige Consumer Healthcare Inc


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    74112D101


    (CUSIP Number)

    December 29, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 74112D101

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Dimensional Fund Advisors LP
    30-0447847
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [X]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware Limited Partnership

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 3,377,473 ** see Note 1 **
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 3,434,500 ** see Note 1 **
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,434,500 ** see Note 1 **
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.9%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Prestige Consumer Healthcare Inc
    (b) Address of Issuer's Principal Executive Offices
    660 White Plains Road, Suite 250, Tarrytown, NY 10591
    Item 2.
    (a) Name of Person Filing
    Dimensional Fund Advisors LP
    (b) Address of Principal Business Office or, if None, Residence
    6300 Bee Cave Road, Building One, Austin, TX 78746
    (c) Citizenship
    Delaware Limited Partnership
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    74112D101
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    3,434,500 ** see Note 1 **
    (b) Percent of Class:
    6.9%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 3,377,473 ** see Note 1 **
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 3,434,500 ** see Note 1 **
    (iv) shared power to dispose or to direct the disposition of 0
    ** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dimensional Fund Advisors LP
    By: Dimensional Holdings Inc., General Partner
    By: /s/ Selwyn Notelovitz
    Date: February 14, 2024
    Name: Selwyn Notelovitz
    Title: Global Chief Compliance Officer

    Get the next $PBH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    11/5/2021$123.00 → $126.00Sector Perform
    RBC Capital
    More analyst ratings

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh

      5/8/25 7:09:10 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which

      5/8/25 6:00:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

      TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10

      4/10/25 5:00:00 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

      Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

      2/10/22 3:58:00 PM ET
      $LEAF
      $PBH
      $SPTN
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    SEC Filings

    See more

    $PBH
    Financials

    Live finance-specific insights

    See more
    • SEC Form 10-K filed by Prestige Consumer Healthcare Inc.

      10-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

      5/9/25 6:06:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

      5/8/25 6:04:33 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

      SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/7/25 7:43:30 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh

      5/8/25 7:09:10 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which

      5/8/25 6:00:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

      TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10

      4/10/25 5:00:00 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prestige Consumer downgraded by Sidoti with a new price target

      Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

      12/9/24 9:05:37 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer upgraded by DA Davidson with a new price target

      DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

      6/21/24 7:05:28 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Prestige Consumer with a new price target

      Canaccord Genuity initiated coverage of Prestige Consumer with a rating of Buy and set a new price target of $71.00

      11/17/22 7:23:24 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

      SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/14/24 10:11:25 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

      SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/14/24 7:09:49 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

      SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/13/24 5:12:15 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lombardi Ronald M. covered exercise/tax liability with 2,305 shares, decreasing direct ownership by 0.66% to 346,529 units (SEC Form 4)

      4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:46:21 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Marketing & Sales Mekhail Adel covered exercise/tax liability with 457 shares, decreasing direct ownership by 2% to 20,908 units (SEC Form 4)

      4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:44:53 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO & COO Sacco Christine was granted 7,775 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 13% to 58,465 units (SEC Form 4)

      4/A - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:43:10 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care